Glenmark Wins US FDA Approval For Inhalation Therapy Medicine With 180 Day Generic Exclusivity
Glenmark Wins US FDA Approval For Inhalation Therapy Medicine With 180 Day Generic Exclusivity is drawing significant interest across the industry.
Glenmark Specialty SA has received final approval from the United States Food and Drug Administration for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. The approval grants the company 180 days of Competitive Generic Therapy exclusivity upon commercialization in the United States.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- ICICI Bank Board Approves Purchase of Additional 2.0% Stake in ICICI Prudential Life Insurance
- Antarctica’s Mineral Riches Exposed as Climate Warms
- What is Netanyahu’s ‘hexagon of alliances’ and why India is at the centre of his Middle East strategy
- UMPI men’s basketball has a shot at its 1st NCAA Tournament
Source: Original →